MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio webcast on Friday, May 29 at 4:30 p.m. ET. MacroGenics management will be joined by external guest presenters to review the preliminary clinical results from the ongoing Phase 1 studies of MGD013 and MGC018 that are part of the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program. To participate in the MacroGenics ASCO 2020 Conference Call, please dial (833) 651-1036 (domestic) or (918) 922-6233 (international) ten minutes prior to the start of the call and provide the Conference ID: 7765546.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2020 after the market closes on Tuesday, May 5, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 5, 2020 at 4:30 p.m. ET. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm.
Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. Here's what you need to know about the businesses behind these recent stock market run-ups before thinking about adding them to a portfolio you'd like to manage successfully.
MGNX earnings call for the period ending March 31, 2020.
MacroGenics (MGNX) delivered earnings and revenue surprises of 9.90% and 84.12%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
As you might know, MacroGenics, Inc. (NASDAQ:MGNX) just kicked off its latest quarterly results with some very strong...
After MacroGenics (NASDAQ: MGNX) updated investors on its clinical-stage drug pipeline and current financial position, its shares are soaring 171% as of 12:45 am EDT Wednesday. After the market's closing bell on Tuesday, the biotech company's management said it remains on track to report final overall survival (OS) data for the phase 3 SOPHIA study of margetuximab in HER2-positive metastatic breast cancer this year. If the data is solid, MacroGenics believes it could get a Food and Drug Administration decision as soon as December 2020.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two of its investigational pipeline molecules. Data covering safety and preliminary anti-tumor activity from the Phase 1 dose escalation and expansion clinical trial of MGD013, a bispecific, tetravalent DART® molecule binding PD-1 and LAG-3, and the Phase 1 dose expansion study of MGC018, an antibody-drug conjugate (ADC) targeting B7-H3, will be presented at the American Society of Clinical Oncology (ASCO) upcoming ASCO20 Virtual Scientific Program to be held May 29-31, 2020.
ROCKVILLE, Md., May 05, 2020 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
Stock soars on promising early trial data for key drugs Continue reading...
Rockville, MD, April 29, 2020 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
Today is shaping up negative for MacroGenics, Inc. (NASDAQ:MGNX) shareholders, with the analysts delivering a...
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule being evaluated in patients with refractory acute myeloid leukemia (AML). The data will be presented during a plenary session at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 27-28, 2020.
Optimism is growing ahead of the release of abstracts this week for the upcoming ASCO 2020 conference.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) will now be held by means of a virtual format only due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and related recommendations and orders from federal and state governmental authorities. The date and time of the meeting, May 14, 2020 at 9:00 a.m. ET, as disclosed in MacroGenics’ proxy statement for the meeting, has not changed. Stockholders will not be able to attend the 2020 Annual Meeting in person.
Q1 2020 MacroGenics Inc Earnings Call
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to support registration in the U.S. of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia (AML) who are refractory to induction therapy. Informed by recent discussions with the U.S. Food and Drug Administration (FDA), the Company plans a single-arm, registration-enabling clinical study to evaluate flotetuzumab in up to 200 patients with primary induction failure (PIF) or early relapse (ER) AML.
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.
In 2001, Scott Koenig was appointed CEO of MacroGenics, Inc. (NASDAQ:MGNX). First, this article will compare CEO...